The Early Perfusion Image Is Useful to Support the Visual Interpretation of Brain Amyloid-PET With 18F-Flutemetamol in Borderline Cases.
Journal
Clinical nuclear medicine
ISSN: 1536-0229
Titre abrégé: Clin Nucl Med
Pays: United States
ID NLM: 7611109
Informations de publication
Date de publication:
01 Sep 2024
01 Sep 2024
Historique:
medline:
6
8
2024
pubmed:
6
8
2024
entrez:
5
8
2024
Statut:
ppublish
Résumé
Visual interpretation of brain amyloid-β (Aβ) PET can be difficult in individuals with borderline Aβ burden. Coregistration with individual MRI is recommended in these cases, which, however, is not always available. This study evaluated coregistration with the early perfusion frames acquired immediately after tracer injection to support the visual interpretation of the late Aβ-frames in PET with 18F-flutemetamol (FMM). Fifty dual-time-window FMM-PET scans of cognitively normal subjects with 0 to 60 Centiloids were included retrospectively (70.1 ± 6.9 years, 56% female, MMSE score 28.9 ± 1.3, 42% APOE ɛ4 carrier). Regional Aβ load was scored with respect to a 6-point Likert scale by 3 independent raters in the 10 regions of interest recommended for FMM reading using 3 different settings: Aβ image only, Aβ image coregistered with MRI, and Aβ image coregistered with the perfusion image. The impact of setting, within- and between-readers variability, region of interest, and Aβ-status was tested by repeated-measure analysis of variance of the Likert score. The Centiloid scale ranged between 2 and 52 (interquartile range, 7-19). Support of visual scoring by the perfusion image resulted in the best discrimination between Aβ-positive and Aβ-negative cases, mainly by improved certainty of excluding Aβ plaques in Aβ-negative cases (P = 0.030). It also resulted in significantly higher between-rater agreement. The setting effect was most pronounced in the frontal lobe and in the posterior cingulate cortex/precuneus area (P = 0.005). The early perfusion image is a suitable alternative to T1-weighted MRI to support the visual interpretation of the late Aβ image in FMM-PET.
Identifiants
pubmed: 39102811
doi: 10.1097/RLU.0000000000005360
pii: 00003072-202409000-00006
doi:
Substances chimiques
flutemetamol
0F3M7032P5
Aniline Compounds
0
Benzothiazoles
0
Amyloid beta-Peptides
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
838-846Informations de copyright
Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of interest and sources of funding: L.E.C. received research support from GE Healthcare and Spinger Healthcare (funded by Eli Lilly). Both contributions have been paid to the institution. There is no actual or potential conflict of interest for the other authors.
Références
Chapleau M, Iaccarino L, Soleimani-Meigooni D, et al. The role of amyloid PET in imaging neurodegenerative disorders: a review. J Nucl Med. 2022;63:13S–19S.
Hosokawa C, Ishii K, Hyodo T, et al. Investigation of (11)C-PiB equivocal PET findings. Ann Nucl Med. 2015;29:164–169.
Oh M, Seo M, Oh SY, et al. Clinical significance of visually equivocal amyloid PET findings from the Alzheimer’s disease neuroimaging initiative cohort. Neuroreport. 2018;29:553–558.
Payoux P, Delrieu J, Gallini A, et al. Cognitive and functional patterns of nondemented subjects with equivocal visual amyloid PET findings. Eur J Nucl Med Mol Imaging. 2015;42:1459–1468.
GE Healthcare. Vizamyl. Summary of product characteristics. European Medicines Agency. 2014. Assessed July 20, 2022.
Minoshima S, Drzezga AE, Barthel H, et al. SNMMI procedure standard/EANM practice guideline for amyloid PET imaging of the brain 1.0. J Nucl Med. 2016;57:1316–1322.
Chen Y, Rosario B, Laymon C, et al. Evaluation of PiB relative delivery value (R-1) as a proxy of relative cerebral blood flow. J Cereb Blood Flow Metab. 2012;32:S170–S171.
Heeman F, Yaqub M, Lopes Alves I, et al. Simulating the effect of cerebral blood flow changes on regional quantification of [(18)F]flutemetamol and [(18)F]florbetaben studies. J Cereb Blood Flow Metab. 2021;41:579–589.
Heeman F, Visser D, Yaqub M, et al. Precision estimates of relative and absolute cerebral blood flow in Alzheimer's disease and cognitively normal individuals. J Cereb Blood Flow Metab. 2023;43:369–378.
Boccalini C, Peretti DE, Ribaldi F, et al. Early-phase (18)F-Florbetapir and (18)F-Flutemetamol images as proxies of brain metabolism in a memory clinic setting. J Nucl Med. 2022;64:266–273.
Daerr S, Brendel M, Zach C, et al. Evaluation of early-phase [(18)F]-florbetaben PET acquisition in clinical routine cases. Neuroimage Clin. 2017;14:77–86.
Hsiao IT, Huang CC, Hsieh CJ, et al. Correlation of early-phase 18F-florbetapir (AV-45/Amyvid) PET images to FDG images: preliminary studies. Eur J Nucl Med Mol Imaging. 2012;39:613–620.
Rostomian AH, Madison C, Rabinovici GD, et al. Early 11C-PIB frames and 18F-FDG PET measures are comparable: a study validated in a cohort of AD and FTLD patients. J Nucl Med. 2011;52:173–179.
Oliveira FPM, Moreira AP, de Mendonca A, et al. Can 11C-PiB-PET relative delivery R1 or 11C-PiB-PET perfusion replace 18F-FDG-PET in the assessment of brain neurodegeneration? J Alzheimers Dis. 2018;65:89–97.
Paulson OB, Hasselbalch SG, Rostrup E, et al. Cerebral blood flow response to functional activation. J Cereb Blood Flow Metab. 2010;30:2–14.
Belohlavek O, Jaruskova M, Skopalova M, et al. Improved beta-amyloid PET reproducibility using two-phase acquisition and grey matter delineation. Eur J Nucl Med Mol Imaging. 2019;46:297–303.
Belohlavek O, Jaruskova M. An easy way to increase confidence in beta-amyloid-PET evaluation. Nucl Med Rev. 2017;20:107–109.
Mathies F, Lange C, Apostolova I, et al. Visual interpretation of amyloid-β PET might be supported by co-registration to the early uptake image. Nuklearmedizin. 2020;59:P154.
Konijnenberg E, Carter SF, Ten Kate M, et al. The EMIF-AD PreclinAD study: study design and baseline cohort overview. Alzheimers Res Ther. 2018;10:75.
Coomans EM, Tomassen J, Ossenkoppele R, et al. Genetically identical twin-pair difference models support the amyloid cascade hypothesis. Brain. 2023;146:3735–3746.
Heeman F, Yaqub M, Alves IL, et al. Optimized dual-time-window protocols for quantitative [F-18]flutemetamol and [F-18]florbetaben PET studies. EJNMMI Res. 2019;9:32.
Klunk WE, Koeppe RA, Price JC, et al. The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET. Alzheimers Dement. 2015;11:1-15.e1–1-15.e14.
Collij LE, Salvado G, Shekari M, et al. Visual assessment of [(18)F]flutemetamol PET images can detect early amyloid pathology and grade its extent. Eur J Nucl Med Mol Imaging. 2021;48:2169–2182.
GE Healthcare. Vizamyl—flutemetamol F18 injection: highlights of prescribing information. 2017.
Buckley CJ, Sherwin PF, Smith AP, et al. Validation of an electronic image reader training programme for interpretation of [18F]flutemetamol beta-amyloid PET brain images. Nucl Med Commun. 2017;38:234–241.
Amadoru S, Dore V, McLean CA, et al. Comparison of amyloid PET measured in Centiloid units with neuropathological findings in Alzheimer’s disease. Alzheimers Res Ther. 2020;12:22.
Pemberton HG, Collij LE, Heeman F, et al. Quantification of amyloid PET for future clinical use: a state-of-the-art review. Eur J Nucl Med Mol Imaging. 2022;49:3508–3528.
DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988;44:837–845.
Knol MJ, Pestman WR, Grobbee DE. The (mis)use of overlap of confidence intervals to assess effect modification. Eur J Epidemiol. 2011;26:253–254.
Zapf A, Castell S, Morawietz L, et al. Measuring inter-rater reliability for nominal data—which coefficients and confidence intervals are appropriate? BMC Med Res Methodol. 2016;16:93.
Landis JR, Koch GG. Measurement of observer agreement for categorical data. Biometrics. 1977;33:159–174.
Levin F, Ferreira D, Lange C, et al. Data-driven FDG-PET subtypes of Alzheimer’s disease-related neurodegeneration. Alzheimers Res Ther. 2021;13:49.
Ward J, Ly M, Raji CA. Brain PET imaging frontotemporal dementia. PET Clin. 2023;18:123–133.
Hu WT, Wang Z, Lee VMY, et al. Distinct cerebral perfusion patterns in FTLD and AD. Neurology. 2010;75:881–888.
Collij LE, Konijnenberg E, Reimand J, et al. Assessing amyloid pathology in cognitively normal subjects using (18)F-flutemetamol PET: comparing visual reads and quantitative methods. J Nucl Med. 2019;60:541–547.
La Joie R, Ayakta N, Seeley WW, et al. Multisite study of the relationships between antemortem [(11)C]PIB-PET Centiloid values and postmortem measures of Alzheimer’s disease neuropathology. Alzheimers Dement. 2019;15:205–216.
Walker Z, Inglis F, Sadowsky C, et al. Reproducibility of [18F]flutemetamol pet amyloid image interpretation. J Neurol Sci. 2013;333:e352.
Cho SH, Choe YS, Kim YJ, et al. Concordance in detecting amyloid positivity between (18)F-florbetaben and (18)F-flutemetamol amyloid PET using quantitative and qualitative assessments. Sci Rep. 2020;10:19576.
Landau SM, Thomas BA, Thurfjell L, et al. Amyloid PET imaging in Alzheimer’s disease: a comparison of three radiotracers. Eur J Nucl Med Mol Imaging. 2014;41:1398–1407.
Johnson KA, Minoshima S, Bohnen NI, et al. Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer’s Association. Alzheimers Dement. 2013;9:e-1–e-16.
Juengling FD, Allenbach G, Bruehlmeier M, et al. Appropriate use criteria for dementia amyloid imaging in Switzerland—mini-review and statement on behalf of the Swiss Society of Nuclear Medicine and the Swiss memory clinics. Nuklearmedizin. 2021;60:7–9.
Rabinovici GD, Knopman D, Arbizu J, et al. Updated Appropriate Use Criteria for Amyloid and Tau PET in Alzheimer’s Disease. 2024. Available at: https://www.alz.org/media/Documents/AUC-Amyloid-Tau-PET-Alzheimers_Manuscript.pdf. Assessed March 17, 2024.